Clearmind Medicine Inc. Common Shares

Clearmind Medicine has entered into a non-binding letter of intent to acquire a 51% majority stake in a company that develops intelligent wireless charging solutions for automated parking systems and autonomous mobile platforms. The aggregate purchase price for the acquisition is $2.5 million, and Clearmind will also extend a $1.5 million loan to the acquired company bearing 4% annual interest, repayable two years after closing. The acquired company’s proprietary technology supports continuous charging up to 10 kW without cables or manual connections and is among the first of its kind commercially deployed for automated parking. Closing is subject to definitive agreements, final due diligence, and other conditions.

Vireo Growth Inc. agreed to acquire Planet 13 Holdings Inc. in an all-stock transaction, one of several major developments in the cannabis and psychedelic sectors this week. Under the deal, each Planet 13 share will be exchanged for 0.015383618 of a Vireo subordinate voting share, representing a 16.6% premium to Planet 13's 20-day volume-weighted average share price as of July 24, 2026. The acquisition will add 36 dispensaries, three cultivation and production facilities, a distribution license, and a cannabis consumption lounge license to Vireo's portfolio, and following this and previously announced acquisitions, Vireo expects to operate approximately 265 dispensaries across 15 states. Separately, SNDL Inc. completed its acquisition of key assets from U.S. cannabis operator Parallel, gaining control of 56 retail locations and three cultivation and manufacturing facilities in Florida, Texas, and Massachusetts, and now supports a 249-store cannabis retail network. Tilray Brands reported record fiscal 2026 net revenue of $915.5 million, an 11% increase from the prior year, while its annual net loss narrowed sharply to $105.2 million from nearly $2.2 billion. In the psychedelic sector, Eli Lilly and Company announced a deal worth up to $3.8 billion to acquire AtaiBeckley Inc., including an upfront cash payment valuing the company at approximately $2.8 billion and an additional $1 billion in contingent milestone payments. Clearmind Medicine reported positive safety results from Part A of its Phase I/II trial of CMND-100 for Alcohol Use Disorder, with all 24 healthy volunteers completing treatment and no serious adverse events reported.

Clearmind Medicine's CMND-100 has met its primary endpoint of safety and tolerability in Part A of an ongoing Phase 1/2 trial for Alcohol Use Disorder. The study enrolled 24 healthy volunteers across four single-ascending-dose cohorts of approximately 20 mg, 40 mg, 80 mg and 160 mg, with all participants completing treatment according to protocol. No serious adverse events were reported, and overall tolerability remained consistent across all four cohorts. CMND-100 is an oral formulation of 5-methoxy-2-aminoindane, a non-hallucinogenic neuroplastogen-derived compound designed to promote adaptive neuroplasticity without the perceptual effects of classical psychedelics. The multicenter trial is being conducted under FDA oversight at institutions including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. Clearmind intends to advance the program into subsequent stages, including dosing patients with Alcohol Use Disorder, following completion of the full Part A dataset analysis.

Clearmind Medicine Inc. released positive ex vivo data for its intranasal MEAI formulation, showing improved retention compared to standard formulae. The study used freshly isolated rabbit mucosal tissue and found that the company's proprietary mucoadhesive formulation maintained a greater proportion of its initially adhered dose over a 30-minute period. MEAI is an investigational non-hallucinogenic neuroplastogen being developed for alcohol use disorder, addiction, and weight loss management. Clearmind's lead MEAI candidate, CMND-100, is designed for treating alcohol use disorder. Shares of Clearmind were trading at $2.16, up 1.06%.

Clearmind Medicine provided an update from its ongoing first-in-human Phase I/IIa trial of CMND-100 for alcohol use disorder, with principal investigators from Yale and Johns Hopkins conveying a generally positive early impression. The investigators highlighted the non-hallucinogenic profile of MEAI, which differentiates it from classical psychedelics and could enable a simpler treatment model without hospitalization or intensive monitoring. Recruitment has progressed well despite strict eligibility criteria, and a promising early safety profile has been observed with no meaningful adverse effects or cardiac safety concerns to date. The study is evaluating CMND-100, Clearmind's novel non-hallucinogenic compound, in a trial that is part of the company's broader neuroplastogen-derived therapeutics pipeline.

Clearmind Medicine has submitted a formal response to the U.S. Department of Health and Human Services Request for Information on addiction treatment innovations as part of the Great American Recovery Initiative. The company highlights its proprietary MEAI-based candidate CMND-100, a non-hallucinogenic neuroplastogen for alcohol use disorder and binge behaviors, emphasizing that AUD affects approximately 10% of the U.S. population with only 1 in 10 receiving treatment. Clearmind proposes an at-home, scalable solution with low abuse potential designed to engage neural pathways such as 5-HT1A to support moderation and long-term recovery. CEO Dr. Adi Zuloff-Shani stated that research at Yale and Johns Hopkins indicates MEAI is well-positioned to lead in these efforts, and the submission underscores the company's commitment to science-driven, non-opioid solutions.